

RAB IV Weekly

August 28, 2020

OPP Interest

*****Nothing to Report*****

HED Interest

**** SENSITIVE – NOT FOR DISTRIBUTION ****

Conference Call on Buprofezin Label Revision for Registration Review Risk

Mitigation. Members of HED and PRD participated in a conference call with the registrant for buprofezin to discuss label revisions required under the Buprofezin Interim Decision (ID) to specify application rates for indoor fogging of greenhouses. The registrant presented information regarding fogging equipment permitted on the label. New information regarding the dilution rate for fogging equipment in greenhouses in terms of gallons applied to a defined area which were provided after the DRA was completed were discussed and this new information will be considered in conjunction with the ID requirements. (Brian Van Deusen, (703) 347-8025).

RAB IV Completed the Draft Human Health Risk Assessment for Difenconazole.

RAB IV completed the draft human health risk assessment (DRA) to support registration review for difenconazole. The hazard characterization, as well as, the dietary, residential, aggregate, and occupational risk assessments for difenconazole were updated for the DRA. A quantitative spray drift assessment was also conducted. Updates to the hazard characterization included removal of dermal endpoints and higher points of departure (compared to previous risk assessment) for all other endpoints, with the exception of the acute dietary endpoint. There were no risk estimates of concern identified in the assessment. The RAB IV risk assessment team included: Bonnie Cropp-Kohlligian, Minerva Mercado-Feliciano, Thurston Morton, and Carolyn Mottley. (Bonnie Cropp-Kohlligian, 703-305-7462).

Branch Interest/Activities

*****Nothing to Report*****